Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Potential carve outs for M&A voting agreements. Stockholder litigation.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Cooley M&A

JANUARY 25, 2023

Tech M&A in 2022 was a tale of two halves. billion [1] during the first half of 2022 to $189.17 billion in the second half, resulting in total 2022 volume of $720.3 billion [1] during the first half of 2022 to $189.17 billion in the second half, resulting in total 2022 volume of $720.3 trillion. [2] trillion.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

OfficeHours

AUGUST 20, 2023

Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank. You must be able to consider long-term goals, assess risk, and craft plans to enhance the value of portfolio companies. Join OfficeHours Today!

Private Equity 130

Private Equity Equities Investment Banking Finance 130

TechCrunch: M&A

JUNE 26, 2023

“We are so excited to be joining IBM and combining our industry leading offerings with IBM’s global presence and strong portfolio across AIOps, automation and hybrid cloud offerings.” The second is that it’s worth watching to see what happens next across the PE landscape.

Management 46

Management Acquisitions Business IT 46

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity. billion, Mirati for $5.8

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JANUARY 20, 2022

While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. approved prescription cannabidiol medicine to its portfolio. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Mergers and Inquisitions

NOVEMBER 1, 2023

They do not invest in risky biotech startups attempting to cure cancer (at least not within their traditional PE portfolios). What about when the IPO market is shut down and exits look uncertain? For more on this, please see our healthcare investment banking article. in biology. For healthcare, most of the risks are regulatory.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

FEBRUARY 1, 2024

2023’s much-discussed downturn in mergers & acquisitions – with global M&A volume and value down 6% and 17%, respectively, from 2022 – was largely driven by the slowdown in the tech sector, with global tech M&A volumes down 51% year over year, while other sectors saw marked increases. [1] in 2022 to 5.9x

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59